Details for New Drug Application (NDA): 207232
✉ Email this page to a colleague
NDA 207232 describes DACTINOMYCIN, which is a drug marketed by Am Regent, Eugia Pharma, Hikma, Hisun Pharm Hangzhou, Meitheal, and Xgen Pharms, and is included in six NDAs. It is available from four suppliers. Additional details are available on the DACTINOMYCIN profile page.
The generic ingredient in DACTINOMYCIN is dactinomycin. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dactinomycin profile page.
The generic ingredient in DACTINOMYCIN is dactinomycin. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dactinomycin profile page.
Summary for 207232
| Tradename: | DACTINOMYCIN |
| Applicant: | Hisun Pharm Hangzhou |
| Ingredient: | dactinomycin |
| Patents: | 0 |
Pharmacology for NDA: 207232
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors Protein Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 207232
Suppliers and Packaging for NDA: 207232
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DACTINOMYCIN | dactinomycin | INJECTABLE;INJECTION | 207232 | ANDA | Hisun Pharmaceuticals USA, Inc. | 42658-008 | 42658-008-01 | 1 VIAL in 1 CARTON (42658-008-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 0.5MG/VIAL | ||||
| Approval Date: | Jul 16, 2019 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
